Exclusive extracts from this 25-page-long report:
- Who is the player?
Sumitomo Chemical is a leading global chemical company with over 100 subsidiaries and 33,000 employees. The group operates through six reporting segments: Petrochemicals & Plastics; Energy and Functional Materials; IT-related Chemicals; Health & Crop Sciences; Pharmaceuticals; and Others (chemical plant engineering, energy, transport and warehousing). [...].
- What are the player's strategies?
In April 2019, the Sumitomo Dainippon Pharma released Mid-term Business Plan 2022, which aims in part to prepare the company for a post-LATUDA scenario. In the US, which will be most affected by the LATUDA revenue shortfall, the company is looking towards the development of new drugs across its three main focus areas – Psychiatry & Neurology, Oncology and Regenerative Medicine. […].
- What are the player's strengths and weaknesses?
Strong presence in Asia, home to some of the world's largest and fastest growing economies (75.7% of sales in FY2018). […]
Main share of group operating profit is generated by high margin specialty chemicals […]
Dependence on naphta feedstock, which remains cost-disadvantaged compared to ethane […]
Intense technology competition in the Asian market, particularly from state-backed Chinese companies […]
- What is the player's financial position?
The financial indicators presented in the report include: Consolidated net revenues, Consolidated operating income and margin, Consolidated net profit and margin, R&D spending and ratio, Sales by segment, Sales performance by segment, Sales by region, Sales performance by region, Profitability ratios, Liquidity ratios, Solvency ratios and Free cash flow and capital expenditure.